Maurice Brownlee, APRN

Baal Perazim Wellness & Health Services Inc.

Disclosure(s): EMD Serono: Grant/Research Support, Honoraria; Gilead Sciences: Grant/Research Support, Honoraria; Napo Pharmaceuticals: Grant/Research Support, Honoraria; ViiV Healthcare: Grant/Research Support, Honoraria

Poster(s):

• (P-396) PREFER-LA: People with HIV (PWH) in the United States with Prior Adherence Challenges with Oral Antiretroviral Therapy (ART) Prefer Cabotegravir + Rilpivirine Long-Acting (CAB+RPV LA) Therapy after Switch
  Monday, October 20, 2025

  12:15 PM - 1:30 PM US ET